In vivo hemin conditioning targets the vascular and immunologic compartments and restrains prostate tumor development

Felipe M. Jaworski, Lucas D. Gentilini, Geraldine Gueron, Roberto P. Meiss, Emiliano G. Ortiz, Paula M. Berguer, Asif Ahmed, Nora Navone, Gabriel A. Rabinovich, Daniel Compagno, Diego J. Laderach, Elba S. Vazquez*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Purpose: Conditioning strategies constitute a relatively unexplored and exciting opportunity to shape tumor fate by targeting the tumor microenvironment. In this study, we assessed how hemin, a pharmacologic inducer of heme oxygenase-1 (HO-1), has an impact on prostate cancer development in an in vivo conditioning model. Experimental Design: The stroma of C57BL/6 mice was conditioned by subcutaneous administration of hemin prior to TRAMP-C1 tumor challenge. Complementary in vitro and in vivo assays were performed to evaluate hemin effect on both angiogenesis and the immune response. To gain clinical insight, we used prostate cancer patient-derived samples in our studies to assess the expression of HO-1 and other relevant genes. Results: Conditioning resulted in increased tumor latency and decreased initial growth rate. Histologic analysis of tumors grown in conditioned mice revealed impaired vascularization. Hemin-treated human umbilical vein endothelial cells (HUVEC) exhibited decreased tubulogenesis in vitro only in the presence of TRAMP-C1-conditioned media. Subcutaneous hemin conditioning hindered tumor-associated neovascularization in an in vivo Matrigel plug assay. In addition, hemin boosted CD8+ T-cell proliferation and degranulation in vitro and antigen-specific cytotoxicity in vivo. A significant systemic increase in CD8+ T-cell frequency was observed in preconditioned tumor-bearing mice. Tumors from hemin-conditioned mice showed reduced expression of galectin-1 (Gal-1), key modulator of tumor angiogenesis and immunity, evidencing persistent remodeling of the microenvironment. We also found a subset of prostate cancer patient-derived xenografts and prostate cancer patient samples with mild HO-1 and low Gal-1 expression levels. Conclusions: These results highlight a novel function of a human-used drug as a means of boosting the antitumor response.

Original languageEnglish
Pages (from-to)5135-5148
Number of pages14
JournalClinical Cancer Research
Volume23
Issue number17
DOIs
Publication statusPublished - 1 Sep 2017

Fingerprint

Hemin
Blood Vessels
Prostate
Heme Oxygenase-1
Neoplasms
Prostatic Neoplasms
Galectin 1
Angiogenesis Modulating Agents
T-Lymphocytes
Cell Degranulation
Tumor Microenvironment
Human Umbilical Vein Endothelial Cells
Conditioned Culture Medium
Inbred C57BL Mouse
Heterografts
Immunity
Research Design
Cell Proliferation
Antigens
Growth

Bibliographical note

© 2017 American Association for Cancer Research

Keywords

  • prostate-cancer
  • eme-Oxygenase-1
  • conditioning
  • inflammation
  • Galectin-1

Cite this

Jaworski, F. M., Gentilini, L. D., Gueron, G., Meiss, R. P., Ortiz, E. G., Berguer, P. M., ... Vazquez, E. S. (2017). In vivo hemin conditioning targets the vascular and immunologic compartments and restrains prostate tumor development. Clinical Cancer Research, 23(17), 5135-5148. https://doi.org/10.1158/1078-0432.CCR-17-0112
Jaworski, Felipe M. ; Gentilini, Lucas D. ; Gueron, Geraldine ; Meiss, Roberto P. ; Ortiz, Emiliano G. ; Berguer, Paula M. ; Ahmed, Asif ; Navone, Nora ; Rabinovich, Gabriel A. ; Compagno, Daniel ; Laderach, Diego J. ; Vazquez, Elba S. / In vivo hemin conditioning targets the vascular and immunologic compartments and restrains prostate tumor development. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 17. pp. 5135-5148.
@article{d4e239daf1894b16b2c46bbbf7810651,
title = "In vivo hemin conditioning targets the vascular and immunologic compartments and restrains prostate tumor development",
abstract = "Purpose: Conditioning strategies constitute a relatively unexplored and exciting opportunity to shape tumor fate by targeting the tumor microenvironment. In this study, we assessed how hemin, a pharmacologic inducer of heme oxygenase-1 (HO-1), has an impact on prostate cancer development in an in vivo conditioning model. Experimental Design: The stroma of C57BL/6 mice was conditioned by subcutaneous administration of hemin prior to TRAMP-C1 tumor challenge. Complementary in vitro and in vivo assays were performed to evaluate hemin effect on both angiogenesis and the immune response. To gain clinical insight, we used prostate cancer patient-derived samples in our studies to assess the expression of HO-1 and other relevant genes. Results: Conditioning resulted in increased tumor latency and decreased initial growth rate. Histologic analysis of tumors grown in conditioned mice revealed impaired vascularization. Hemin-treated human umbilical vein endothelial cells (HUVEC) exhibited decreased tubulogenesis in vitro only in the presence of TRAMP-C1-conditioned media. Subcutaneous hemin conditioning hindered tumor-associated neovascularization in an in vivo Matrigel plug assay. In addition, hemin boosted CD8+ T-cell proliferation and degranulation in vitro and antigen-specific cytotoxicity in vivo. A significant systemic increase in CD8+ T-cell frequency was observed in preconditioned tumor-bearing mice. Tumors from hemin-conditioned mice showed reduced expression of galectin-1 (Gal-1), key modulator of tumor angiogenesis and immunity, evidencing persistent remodeling of the microenvironment. We also found a subset of prostate cancer patient-derived xenografts and prostate cancer patient samples with mild HO-1 and low Gal-1 expression levels. Conclusions: These results highlight a novel function of a human-used drug as a means of boosting the antitumor response.",
keywords = "prostate-cancer, eme-Oxygenase-1, conditioning, inflammation, Galectin-1",
author = "Jaworski, {Felipe M.} and Gentilini, {Lucas D.} and Geraldine Gueron and Meiss, {Roberto P.} and Ortiz, {Emiliano G.} and Berguer, {Paula M.} and Asif Ahmed and Nora Navone and Rabinovich, {Gabriel A.} and Daniel Compagno and Laderach, {Diego J.} and Vazquez, {Elba S.}",
note = "{\circledC} 2017 American Association for Cancer Research",
year = "2017",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-17-0112",
language = "English",
volume = "23",
pages = "5135--5148",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

Jaworski, FM, Gentilini, LD, Gueron, G, Meiss, RP, Ortiz, EG, Berguer, PM, Ahmed, A, Navone, N, Rabinovich, GA, Compagno, D, Laderach, DJ & Vazquez, ES 2017, 'In vivo hemin conditioning targets the vascular and immunologic compartments and restrains prostate tumor development', Clinical Cancer Research, vol. 23, no. 17, pp. 5135-5148. https://doi.org/10.1158/1078-0432.CCR-17-0112

In vivo hemin conditioning targets the vascular and immunologic compartments and restrains prostate tumor development. / Jaworski, Felipe M.; Gentilini, Lucas D.; Gueron, Geraldine; Meiss, Roberto P.; Ortiz, Emiliano G.; Berguer, Paula M.; Ahmed, Asif; Navone, Nora; Rabinovich, Gabriel A.; Compagno, Daniel; Laderach, Diego J.; Vazquez, Elba S.

In: Clinical Cancer Research, Vol. 23, No. 17, 01.09.2017, p. 5135-5148.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vivo hemin conditioning targets the vascular and immunologic compartments and restrains prostate tumor development

AU - Jaworski, Felipe M.

AU - Gentilini, Lucas D.

AU - Gueron, Geraldine

AU - Meiss, Roberto P.

AU - Ortiz, Emiliano G.

AU - Berguer, Paula M.

AU - Ahmed, Asif

AU - Navone, Nora

AU - Rabinovich, Gabriel A.

AU - Compagno, Daniel

AU - Laderach, Diego J.

AU - Vazquez, Elba S.

N1 - © 2017 American Association for Cancer Research

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose: Conditioning strategies constitute a relatively unexplored and exciting opportunity to shape tumor fate by targeting the tumor microenvironment. In this study, we assessed how hemin, a pharmacologic inducer of heme oxygenase-1 (HO-1), has an impact on prostate cancer development in an in vivo conditioning model. Experimental Design: The stroma of C57BL/6 mice was conditioned by subcutaneous administration of hemin prior to TRAMP-C1 tumor challenge. Complementary in vitro and in vivo assays were performed to evaluate hemin effect on both angiogenesis and the immune response. To gain clinical insight, we used prostate cancer patient-derived samples in our studies to assess the expression of HO-1 and other relevant genes. Results: Conditioning resulted in increased tumor latency and decreased initial growth rate. Histologic analysis of tumors grown in conditioned mice revealed impaired vascularization. Hemin-treated human umbilical vein endothelial cells (HUVEC) exhibited decreased tubulogenesis in vitro only in the presence of TRAMP-C1-conditioned media. Subcutaneous hemin conditioning hindered tumor-associated neovascularization in an in vivo Matrigel plug assay. In addition, hemin boosted CD8+ T-cell proliferation and degranulation in vitro and antigen-specific cytotoxicity in vivo. A significant systemic increase in CD8+ T-cell frequency was observed in preconditioned tumor-bearing mice. Tumors from hemin-conditioned mice showed reduced expression of galectin-1 (Gal-1), key modulator of tumor angiogenesis and immunity, evidencing persistent remodeling of the microenvironment. We also found a subset of prostate cancer patient-derived xenografts and prostate cancer patient samples with mild HO-1 and low Gal-1 expression levels. Conclusions: These results highlight a novel function of a human-used drug as a means of boosting the antitumor response.

AB - Purpose: Conditioning strategies constitute a relatively unexplored and exciting opportunity to shape tumor fate by targeting the tumor microenvironment. In this study, we assessed how hemin, a pharmacologic inducer of heme oxygenase-1 (HO-1), has an impact on prostate cancer development in an in vivo conditioning model. Experimental Design: The stroma of C57BL/6 mice was conditioned by subcutaneous administration of hemin prior to TRAMP-C1 tumor challenge. Complementary in vitro and in vivo assays were performed to evaluate hemin effect on both angiogenesis and the immune response. To gain clinical insight, we used prostate cancer patient-derived samples in our studies to assess the expression of HO-1 and other relevant genes. Results: Conditioning resulted in increased tumor latency and decreased initial growth rate. Histologic analysis of tumors grown in conditioned mice revealed impaired vascularization. Hemin-treated human umbilical vein endothelial cells (HUVEC) exhibited decreased tubulogenesis in vitro only in the presence of TRAMP-C1-conditioned media. Subcutaneous hemin conditioning hindered tumor-associated neovascularization in an in vivo Matrigel plug assay. In addition, hemin boosted CD8+ T-cell proliferation and degranulation in vitro and antigen-specific cytotoxicity in vivo. A significant systemic increase in CD8+ T-cell frequency was observed in preconditioned tumor-bearing mice. Tumors from hemin-conditioned mice showed reduced expression of galectin-1 (Gal-1), key modulator of tumor angiogenesis and immunity, evidencing persistent remodeling of the microenvironment. We also found a subset of prostate cancer patient-derived xenografts and prostate cancer patient samples with mild HO-1 and low Gal-1 expression levels. Conclusions: These results highlight a novel function of a human-used drug as a means of boosting the antitumor response.

KW - prostate-cancer

KW - eme-Oxygenase-1

KW - conditioning

KW - inflammation

KW - Galectin-1

UR - http://www.scopus.com/inward/record.url?scp=85029514027&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-0112

DO - 10.1158/1078-0432.CCR-17-0112

M3 - Article

AN - SCOPUS:85029514027

VL - 23

SP - 5135

EP - 5148

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -